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I N T R O D U C T I O N
In general, tumor cells have an accelerated metabolism as compared to 
their normal counterparts in accordance with their higher cell growth and 
proliferation rate (1-6). Overall anabolic routes are enhanced in tumor 
cells, whereas catabolic routes are less active. This imbalance increases 
with the malignant state of the tumor cells (1, 2, 7, 8) and can be used as 
a tool for cancer therapy. No wonder that drugs, which resemble naturally 
occurring cellular metabolites, are used in target-directed anticancer 
therapy.
Antimetabolites of purine and pyrimidine are of great interest because 
they may incorporate into DNA and RNA of tumor cells and as such 
may even inhibit the synthesis of these polynucleotides. The thiopurine 
antimetabolites 6-mercaptopurine (6MP) and 6-thioguanine (6TG) form the 
cornerstone of regimens in treatment of malignancies (9-12). The metabolic 
action of 6MP and 6TG are closely related (Fig. 1). 6MP as well as 6TG 
are initially converted by hypoxanthine-guanine phosphoribosyltransferase 
(HGPRT, EC 2.4.2.8) to 6-thio~IMP (t-IMP) and 6-thio-GMP (t-GMP), 
respectively. Further conversion of t-IMP to t-GMP via 6-thio-XMP is 
catalyzed by two enzymes, IMP dehydrogenase (IMPDH, EC 1.2,1.14) 
and GMP synthetase (GMPS, EC 6.3.4.1) respectively. Subsequently, 
t-GMP is converted by consecutive steps to 6-thio-GTP (t-GTP) and 
6-thio-deoxy-GTP (t-dGTP), which are incorporated into RNA and DNA, 
respectively.
At present it is generally accepted that incorporation of t-dGTP into 
DNA is the most important reason for cytotoxicity of 6MP and 6TG, 
inducing DNA damage, such as single strand breaks, DNA-protein cross­
links, interstrand cross-links and sister chromatid exchanges (13-18).
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FIG. 1. 6-Thiopurine metabolism (left) and purine metabolism (right), 1. hypoxanthine- 
guanine phosphoribosyltransferase (HGPRT); 2. IMP dehydrogenase (IMPDH); 3. GMP 
synthetase (GMPS); 4. thiopurine methyltransferase (TPMT); 5. adenosine kinase (AK);
6. PRPP amido transferase,
However, 6MP seems to provoke cytotoxicity in a more complex manner 
than 6TG.
Metabolites from 6MP can also be methylated to methylmercaptopurines 
(Fig. 1). The thiopurine méthylation is catalyzed by thiopurine methyl­
transferase (TPMT, EC 2.1.1.67) and is S-adenosyl-L-methionine de­
pendent (19-21).
The importance of the méthylation route for 6MP cytotoxicity has not 
yet been fully elucidated. Methyl-thio-IMP (me-t-IMP), the predominant 
metabolite formed by méthylation of 6MP, is a strong inhibitor of PRPP 
amidotransferase (EC 2,4.2.14) the second enzyme of de novo purine 
synthesis (19, 22, 23). PRPP amidotransferase catalyzes the conversion 
of PRPP to PRA. This inhibition by me-t-IMP can induce cytotoxicity by 
several mechanisms.
Inhibition of PRPP amidotransferase results in accumulation of PRPP. 
Since PRPP is a co-substrate for intracellular conversion of 6MP to t-IMP, 
increase of PRPP induces an increased anabolism of 6MP and as such 6MP 
cytotoxicity is stimulated (23, 24).
A depletion of endogenous nucleotides is observed due to decreased de 
novo purine synthesis by me-t-IMP (23, 25). Tumor cells have a high need
of purine metabolites for cell growth and cell proliferation and these cells 
are highly dependent on de novo purine synthesis (PDNS). So, depletion 
of purine nucleotides results in decreased RNA and DNA synthesis (23).
Increase of PRPP, which results from inhibition of PRPP amidotrans­
ferase, induces an enhanced biosynthesis of pyrimidines, because this 
pathway is regulated by PRPP (23, 26). Increase of pyrimidine nucleotides 
in combination with decrease of purine nucleotides may lead to unbalanced 
cell growth and this may also contribute to cell death of tumor cells.
The effects of me-t-IMP could be confirmed, in experiments with 
methylmercaptopurine riboside (me-MPR) (26, 27). This cytostatic drug 
is an analogue of the purine nucleoside adenosine (Fig. 1). Earlier studies 
(28) demonstrated that me-MPR is effective in experimental tumor cells 
resistant to 6MP. Probably this is due to the fact that development of 
cellular resistance to 6MP is commonly associated with loss of HGPRT 
activity. Under these conditions the resistant cells are more dependent 
on the de novo purine synthesis. Me-MPR is converted into me-t-IMP 
by adenosine kinase (AK, EC 2.7.1.20). As discussed, me-t-IMP inhibits 
de novo purine synthesis and this may be the reason why cells resistant to 
6MP are more sensitive to me-MPR.
Our recent in vitro studies confirm the important role of me-t-IMP 
formation and we have provided evidence that me-t-IMP may provoke 
cytotoxicity in tumor cells by a more complex mechanism (23, 27, 29, 30). 
The studies were performed in Molt F4 cells, a T-cell acute lymphoblastic 
leukemia cell line. The first indications for the importance of me-t-IMP 
for 6MP cytotoxicity is the observed synergism between 2 jjlM 6MP and
0.5 |jlm mycophenolic acid (MPA) on cell viability and cell growth 
(31). Since IMPDH is involved in the conversion of t-IMP to t-GMP, 
inhibition of this enzyme by MPA will decrease the formation of 6TG 
nucleotides. Ultimately, inhibition of the formation of 6TG nucleotides 
will result in diminished incorporation of 6TG nucleotides into DNA and 
RNA. Indeed, during the first 24 hr after MPA and 6MP, less t-GMP 
was measured as compared to 6MP alone. Furthermore, much higher 
me-t-IMP concentrations were detected after combination of 0.5 jjlm MPA 
(27). The observation that both cytotoxicity and Me-t-IMP concentration 
are increased after combination of MPA and 6MP treatment indicates 
that me-t-IMP formation is indeed of importance for cytotoxicity of 
6MP in lymphoblastic cells with an active de novo purine synthesis. 
The inhibition of de novo purine synthesis is studied with increasing 
concentrations of me-MPR, and 0.1 fxM me-MPR already resulted in 
maximal inhibition of de novo purine synthesis and increase of PRPP. The 
me-t-IMP concentration which induces a maximal PRPP concentration is 
approximately 500 pmol/106 cells in this cell line (27).
The inhibition of de novo purine synthesis by me-t-IMP is examined in
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more detail by simultaneous prevention of purine nucleotide depletion 
by addition of aminocarboxamide ribonucleoside (AICAR). AICAR is 
incorporated distal to the site of inhibition of de novo purine synthesis 
by me-t-IMP. Addition of 50 julm AICAR indeed results in prevention 
of depletion especially of adenine nucleotides and subsequent decrease 
of cytotoxicity by 6MP and me-t-IMP (29). Similar effects are observed 
in combinations of intermediates of purine salvage adenosine, adenine, 
and inosine with 6MP or me-MPR, i.e., depletion of adenine nucleotides 
is prevented and less cytotoxicity is observed (30). So, these data 
clearly present evidence that me-t-IMP contributes to 6MP cytotoxicity 
in malignant cells with an active de novo purine synthesis.
MATERIALS AND METHODS
Materials. [i4C-CH3]-methionine was purchased from Amersham (UK). 
6MP, me-MPR, SAM and SAH were obtained from Sigma (St. Louis, . 
MO, USA).
Procedures. Cell culture. The studies were performed with Molt F4 
cells. Cells were grown in RPMI 1640 DM medium (Gibco, Netherlands), 
containing 10% non-dialyzed fetal calf serum (Gibco, Netherlands), 2 mM 
L-glutamine (Sigma, St. Louis, MO, USA), 2 mM sodium pyruvate (BDH 
Chemicals Ltd, UK) and gentamicin/streptomycin, thrice a week. The cell 
cultures were maintained in a humidified 5% C02 atmosphere at 37°C. 
The absence of mycoplasma contamination and the presence of marker 
antigens were tested regularly.
Incubation procedure. Experiments were started with logarithmically 
growing cells at an initial cell number of 0.3 x 106 cells/ml, before 
addition of the drugs. 6MP and Me-MPR were added as a single dose in 
a small VOL (l/100v/v) and the cells were incubated for 24 hr with either 
of these drugs. After incubation, the cells were harvested and counted with 
a Coulter counter. Cell viability was determined by means of trypan blue 
exclusion. Cell growth was determined by counting the cells and correcting 
cell number for cell viability.
DNA méthylation. After incubation with the drug, 500 fil pulse 
medium (0.198 mM [14C-CH3]-methionine (50.4 mCi/mmol) in RPMI 
1640 DM) was added to the cell pellet and the cells were incubated for 
another 2 hr at 37°C. After pronase treatment, DNA was isolated by 
phenol/chloroform extraction and dissolved in 300 jxl 100 mM Tris + 1 
mM EDTA buffer, pH 7.5. From this solution, 100 jjlI  was counted by 
liquid scintillation.
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Determination of SAM concentrations. SAM concentrations were deter­
mined by HPLC in 107 viable cells according to the method described by 
Molloy et aL (32).
RESULTS AND DISCUSSION
Effects of 6-Mercaptopurine on the Transmethylation Route
Recently we postulated a new mechanism by which formation of 
me-t-IMP from 6MP may disturb various cellular processes, thereby 
inducing cytotoxicity (30). Treatment of Molt F4 cells, a human malignant 
lymphoblastic cell line, with 6MP results in a depletion of SAM and an 
increase of methionine and S-adenosyl-L-homocysteine (SAH), leading to 
a concentration dependent decrease of the intracellular SAM/SAH ratio 
(Fig. 2).
The depletion of SAM can be ascribed to two mechanisms. First, 
SAM acts as co-substrate for the méthylation of 6MP metabolites into 
methylthiopurines (Fig. 3), so SAM may become depleted during the 
méthylation of thiopurines. Second, as a result of Me-t-IMP formation, 
de novo purine synthesis is inhibited and ATP becomes depleted. Formation 
of SAM from methionine (Fig. 3) is ATP dependent, so conversion of 
methionine to SAM will be hampered under these conditions.
To discriminate between these two effects, experiments were performed 
with me-MPR. Overall the effects of me-MPR on the SAM, SAH and 
methionine pools closely resemble the effects of 6MP, i.e., SAM is 
depleted and SAH is increased (30). Me-MPR is already methylated, 
so this means that the conversion of me-MPR to me-t-IMP is a process 
which is independent of SAM. On the other hand, conversion of me-MPR 
to me-t-IMP by AK consumes ATP, since ATP is the co-substrate of this 
conversion. Moreover, me-MPR competitively inhibits the conversion of 
adenosine tp AMP. So, me-MPR indirectly inhibits re-synthesis of ATP 
via salvage as well as de novo purine synthesis. Both inhibitions lead to 
depletion of ATP. These findings indicate that the effects of 6MP and 
me-MPR on SAM levels are most likely caused by reduced synthesis 
of SAM, due to decreased ATP levels. However, it cannot be excluded 
that, during treatment with 6MP, methyl transfer may also contribute to 
decreased SAM.
Enzymatic assays were performed to exclude direct inhibition of 
methionine adenosyltransferase (MAT, EC 2.5.1.6) or S-adenosylhomo- 
cysteine hydrolase (SAHH, EC 3.3.1.1) by metabolites of 6MP. Enzyme 
activities of MAT and SAH were measured in presence of 6MP, and 
me-MPR, t-IMP, me-t-IMP, respectively. None of these antimetabolites 
show any inhibition of MAT or SAHH (Table 1).
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FIG. 2. Effects of 10 fxM 6MP and 10 fxM me-MPR, respectively, on the SAM/SAH ratio, 
the methionine concentration and the ATP concentration after 24 hr treatment of Molt 
F4 cells. Methionine and ATP concentrations are expressed as pmol/10ft viable cells; means
and range (between brackets) of 4 experiments.
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FIG, 3. Transmethylation pathway. 1. SAM-dependent mcthyltransferases (e.g. TPMT);
2. S-adenosyl-L-homocyteine hydrolase (SAHH); 3, methionine synthase; 4, methionine
adcnosyltransferase (MAT); 5. cystathionine synthase.
TABLE 1. MAT AND SAHH ACTIVITIES, MEASURED IN 
THE PRESENCE OF 6MP AND ITS METABOLITES
MAT activity (n=5) SAHH activity (««6) 
(mean ± SD) (mean ± SD)
Without drug 2.85 ± 0.52 4.01 ± 0.35
10 fxM 6MP 2.87 ± 0.22 3.97 ± 0.35
10 |JLM me-MPR 3.37 ± 0.36 3.97 ± 0.36
10 jxM t-IMP 2.84 ± 0.38 4.65 ± 0.07
10 |xM me-t-IMP 2.92 ± 0.30 4.06 ± 0.54
Enzyme activities are nmol x 1(H' cells X hr-1 and are measureed 
in quadruplicate
(n = number of experiments, SD = standard deviation).
The observation that 6MP and me-t-IMP cause a decrease of the 
SAM/SAH ratio may help unravel the complexity of 6MP cytotoxicity. 
SAM is a methyl-donor for a great number of methyltransferase reactions, 
and is involved in méthylation of e.g., DNA and RNA, proteins and 
phospholipids (33, 34),
Experiments have been performed to study whether depletion of SAM 
by 6MP or me-t-IMP results in disturbance of DNA méthylation in human 
malignant cells. Logarithmically growing Molt F4 cells were incubated 
for 24 hr with either 2 \xM 6MP, 10 |ulM 6MP, 0.5 fxM me-MPR or 
2 (xM me-MPR. Untreated cells were used for reference. The 24 hr 
incubation was followed by a 2 hr kpulse' with [14C-CH3]-methionine. 
DNA was isolated and quantified and radioactivity was counted.
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TABLE 2. EFFECTS OF 6MP AND ME-MPR ON THE SAM 
CONCENTRATION AND DNA METHYLATION
SAM (nmol/107 viable cells) [,4C-CH3]-DNA incorporation
(% of control)
(mean ± SD) (mean ± SD) 
100Control (without drug) 
2 |xM 6MP 
10 |xm 6MP 
0.5 jjlM me-MPR 
2 [xm me-MPR
5.1 ± 0.2 
2.8 ± 0.4 
1.5 ± 0.8
1.7 ± 0.4
1.7 ± 0.3
24 ± 1 
18 ± 5
22 ± 12 
19 ± 12
Mean ± standard deviation (SD) are from 3 experiments in quadruplicate.
DNA méthylation is decreased significantly by 6MP and me-MPR as 
compared with untreated cells (Table 2).
The observation that 6MP and me-MPR cause DNA hypomethylation 
as a consequence of depletion of SAM may have a great impact on 
cytotoxicity and tumor progression. In human DNA, cytosine residues 
are methylated in specific sequences, by which two cytosine residues 
are sequenced by two guanine residues. The méthylation status of these 
so-called CpG sites is involved in the multilevel genetic control system 
regulating differentiation processes and gene expression (35, 36). The 
extent to which DNA méthylation contributes to the differentiation of 
hematopoietic cells is not yet fully understood.
In human malignant cells, regional areas of hypermethylation (CpG 
islands) co-exist with a more widespread hypomethylation status (36, 37). 
This is in contrast with normal cells, where most of the widely dispersed 
CpG sites in bulk chromatin and in the body of genes are methylated, while 
the CpG islands are normally not methylated. Furthermore, malignant cells 
have an increased cellular capacity for méthylation (36).
From recent reports (35, 38, 39) it appears that global DNA hypo­
methylation may be a nonspecific change in tumors and potentially of 
less functional importance than the more regional hypermethylated CpG 
islands. There is a growing evidence that abnormal CpG island méthylation 
is an important factor in the altered gene expression observed in human 
tumors. Abnormal CpG island méthylation on autosomal chromosomes 
occurs at a surprisingly high frequency in immortalized rodent and human 
cells (40).
Recently abnormal DNA méthylation patterns have been associated with 
hematopoietic malignancies. It has been reported (41) that the calcitonin 
gene is hypermethylated in human lymphoblastic and myeloid leukemia. 
Other reports (42,43) show that the same gene is abnormally methylated in 
accelerated or blast crises phase of chronic myeloid leukemia. In a majority
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of patients with acute myeloid leukemia (95%) and acute lymphoblastic
leukemia (90%), DNA from tumor cells shows hypermethylation at the 
5' end of the calcitonin gene (42).
Chemopreventive Effects of SAM
Several reports indicate that SAM and its precursor, methionine, may 
prevent the development of liver and mammary gland carcinomas or 
sarcomas induced in rats or mice by various carcinogens (44, 45). The 
mechanisms underlying the chemoprotective effect of SAM are far from 
being completely elucidated.
Recent data have excluded the dependency of this effect upon production 
of 5-methylthioadenosine, a catabolite of SAM which inhibits growth (46). 
The chemoprotective effect of SAM has been tentatively attributed to the 
méthylation and inhibition of expression of growth-related genes, such 
as c-myc, c-Ha-ray and c-Ki-ras, These genes are highly hypomethylated 
and overexpressed in persistent nodules and hepatocellular carcinomas, 
in the absence of SAM (47). However, there is no definitive proof that 
the méthylation of regulatory sequences of gene promoter is responsible 
for inhibition of expression of growth-related genes and nodule growth in 
SAM-treated rats. Nevertheless, the role of DNA méthylation in SAM 
chemopreventive effect is proven by the finding that 5-azacytidine, a 
known inhibitor of DNA methyltransferases (48), largely overcomes the 
inhibitory effects of SAM on the growth of preneoplastic tissue (49). As 
mentioned, 6MP and me-MPR can similarly induce depletion of SAM 
levels and therefore may reverse the protective effects of SAM against 
carcinogenesis. Possible promoting effects of 6MP on carcinogenesis 
have been studied by Matsushima et a i (50) recently in rats. 6MP 
was given as a dietary supplement (50 ppm) for 35 weeks, subsequent 
to wide-spectrum initiation with yV-ethyl-/V~nitrosourea. Various tumors 
were observed in carcinogen-initiated groups. No significant influence of 
6MP on their development, including the occurrence of leukemia, was 
apparent when comparing the 6MP//V-ethyl~/V-nitrosourea group with the 
yV-ethyl-jV-nitrosourea group. The incidences of some proliferative lesions in 
the lung, intestine and kidney, however, in the 6MP/N-ethyk/V-nitrosourea 
group were slightly higher, although not significant. To confirm the negative 
result of promoting effects of 6MP, further studies have to be performed 
based on dose-dependent examinations using several 6MP-dose levels and 
other initiators.
Since 6MP therapy may also induce hypomethylation of DNA in vivo, 
it would be worthwhile to focus in future studies upon consequences for 
gene expression and tumor progression during 6MP treatment of patients 
with acute lymphoid leukemia. This may mark the effectiveness of 6MP
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therapy against tumor progression. These approaches have not yet been 
reported.
S U M M A R Y
The studies described indicate that me-t-IMP formation is an important 
pathway, contributing to cytotoxicity in Molt F4 cells, which exhibit a 
highly active de novo purine synthesis. On three levels cytotoxicity is 
induced during méthylation of thiopurines.
1. Purine synthesis de novo is inhibited during formation of me-t-IMP. 
Inhibition of PDNS results in depletion of purine nucleotides, with 
subsequently diminishing DNA and RNA synthesis.
2. The increased PRPP levels, induced by me-T-IMP, induce increased 
pyrimidine biosynthesis and cause an imbalance in purine nucleotides. 
This imbalance may lead to inhibition of cell growth and after prolonged 
exposure, to cell death.
3. The observed depletion of SAM and the decrease of the SAM/S AH 
ratio may be an additional mechanism by which 6MP and me-MPR exert 
their effects on cell growth and cell viability. Changes in SAM/SAH ratio 
may directly influence méthylation reactions.
The significant decrease of DNA méthylation by 6MP and me-t-IMP may 
influence gene regulation and tumor progression. Administration of SAM 
leads to chemoprevention of rat liver carcinogenesis, indicating a role of 
DNA méthylation in tumor progression.
Besides the effects on méthylation of DNA, a decrease of SAM/SAH 
ratio may also affect other processes, such as méthylation of RNA, proteins 
and phospholipids, thereby disturbing their functionality.
In conclusion, decrease of the SAM/SAH ratio resulting from treatment 
with 6MP and me-MPR may exert many effects in these cells. This may open 
a new field of research, possibly contributing to a deeper understanding of 
the complex mechanisms by which 6MP provokes cytotoxicity.
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